NANOBIOTIX Provides Business Update and Financial Results
Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel...
Source: globenewswire.com
Page 48 - Solid Tumors News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Solid Tumors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Solid Tumors Today - Breaking & Trending Today
Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer
Merck , known as MSD outside of the United States and Canada, and Eisai today provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus...
Source: marketscreener.com
Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
First Phase 3 results for the KEYTRUDA® and Padcev® combination showed a statistically significant and clinically meaningful improvement in OS, PFS and key secondary endpoint of overall response...
Source: marketscreener.com
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)Sep 19, 2023 6:00 AMRegulatory marketing applications for U.S. and EU under review, with plans to expand TEVIMBRA commercial presence worldwideTEVIMBRA is the cornerstone of BeiGene...
Source: pharmiweb.com
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®Sep 19, 2023 6:15 AMEuropean Commission approves TEVIMBRA for previously treated advanced or metastatic esophageal squamous cell carcinoma (ESCC)U.S. FDA accepts Biologics License Ap...
Source: pharmiweb.com